| 1. |
Neijenhuis MK, Kievit W, Perrone RD, et al. The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression. BMC Nephrol, 2017, 18(1): 169.
|
| 2. |
Mladsi D, Zhou X, Mader G, et al. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol, 2024, 25(1): 56.
|
| 3. |
常染色体显性多囊肾病临床实践指南专家委员会. 中国常染色体显性多囊肾病临床实践指南(第二版). 临床肾脏病杂志, 2019, 19(4): 227-235.
|
| 4. |
王强, 朱一辰. 常染色体显性遗传性多囊肾病肾移植临床技术操作规范(2022 版). 器官移植, 2023, 14(1): 24-30.
|
| 5. |
Bolignano D, Palmer SC, Ruospo M, et al. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database Syst Rev, 2015, 2015(7): CD010294.
|
| 6. |
Krummel T, Cellot E, Thiery A, et al. Hemodialysis without anticoagulation: less clotting in conventional hemodialysis than in predilution hemodiafiltration. Hemodial Int, 2019, 23(4): 426-432.
|
| 7. |
孙献坤, 王芳, 陈志文, 等. 无抗凝剂连续性肾脏替代治疗生理盐水冲洗体外循环回路的研究进展. 华西医学, 2023, 38(7): 1073-1076.
|
| 8. |
Oh HS, Kim T, Gu DH, et al. Pharmacokinetics of Nafamostat, a potent serine protease inhibitor, by a novel LC-MS/MS analysis. Molecules, 2022, 27(6): 1881.
|
| 9. |
Maruyama Y, Yoshida H, Uchino S, et al. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study. Int J Artif Organs, 2011, 34(7): 571-576.
|
| 10. |
中华医学会肾脏病学分会专家组. 连续性肾脏替代治疗的抗凝管理指南. 中华肾脏病杂志, 2022, 38(11): 1016-1024.
|
| 11. |
王斌霞, 唐莲, 李兰. 1 例抗磷脂综合征合并 HELLP 综合征患者肾脏替代治疗期间的抗凝治疗分析和药学监护. 中国药师, 2022, 25(6): 1040-1044.
|
| 12. |
敖广宇, 黄兰, 陈亭宇, 等. 血液透析中甲磺酸萘莫司他抗凝的血药浓度与抗凝有效性观察. 中国血液净化, 2023, 22(8): 579-583.
|
| 13. |
胡雪峰, 刘志刚, 李鹏, 等. 萘莫司他对血液透析高危出血倾向患者的治疗效果研究. 长春中医药大学学报, 2024, 40(1): 99-102.
|
| 14. |
安琪, 经天宇, 查镜凯, 等. 基于决策树模型的甲磺酸萘莫司他与普通肝素用于连续肾脏替代治疗抗凝的最小成本分析. 中国循证医学杂志, 2023, 23(2): 139-146.
|
| 15. |
de Jong Y, van der Willik EM, Milders J, et al. Person centred care provision and care planning in chronic kidney disease: which outcomes matter? A systematic review and thematic synthesis of qualitative studies: care planning in CKD: which outcomes matter?. BMC Nephrol, 2021, 22(1): 309.
|
| 16. |
刘洋, 刘秀秀. 预见性护理模式在临床护理实践中运用的现状. 全科护理, 2015, 13(19): 1815-1817.
|
| 17. |
汤娴婷. 预见性护理对血液透析患者低血压发生的影响. 现代养生, 2024, 24(6): 438-441.
|
| 18. |
张铁. 血液透析过程中发生凝血的相关因素及护理进展. 中国冶金工业医学杂志, 2023, 40(1): 17-18.
|
| 19. |
王春玲, 谭娟, 娄苗. 多学科营养护理干预对血液透析高磷血症患者控磷饮食依从性、钙磷代谢和营养状况的影响. 临床与病理杂志, 2023, 43(6): 1281-1288.
|
| 20. |
龚艳琳, 郜欣悦, 陈静, 等. 维持性血液透析患者益处发现体验的质性研究. 中华护理杂志, 2024, 59(2): 164-169.
|
| 21. |
周娟, 张競, 石卉慧. 预见性护理在预防宫颈癌术后并发症中的应用价值. 中华全科医学, 2022, 20(12): 2168-2171.
|
